“We know that our customers need to provide novel, reliable and consistent products to their consumers and patients,” said Angela Strzelecki, p...
New sites at Darmstadt and Hamburg complement Merck’s global integrated mRNA service network with pre-clinical to commercial capabilities Company&...
MDxHealth SA (NASDAQ/Euronext: MDXH), a leading commercial-stage precision diagnostics company, today announced a research collaboration with the Universit...
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (OR...
QIAGEN announced the extension of its eco-friendlier QIAwave product line with the addition of two new nucleic acid extraction kits: the QIAwave RNeasy Plu...
In the world of biotechnology and pharmaceuticals, innovation is the lifeblood of progress. And in the picturesque Basel area, this spirit of innovation is...
Paratek's successful commercialization platform to advance novel therapies developed organically and through acquisitions Paratek adds 'final-mile' capa...
Patents valid through 2038 Clinical topline results from Phase 2b ALS trial expected in H2 2023 Corresponding patents have b...
Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more tha...
Abbott to commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East and Africa Spain-based gl...
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced that the European Unified Patent Court ("UPC") issued a...
AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine is currently available Evaxion’s proprietary ...
- Pharmanovia acquires 11 CNS brands, including Frisium® (clobazam) and Gardenal® (phenobarbital) - The portfolio is available in more than 60 mar...
Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigim...
© 2025 Biopharma Boardroom. All Rights Reserved.
